Gilead Sciences (GILD) FCF Margin Growth (1y) (2010 - 2026)
Gilead Sciences (GILD) FCF Margin Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1,688.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1,334.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1,096.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -647.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -158.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1,388.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3,383.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1,020.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 69.00 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 517.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,383.00 |
| Mar 31, 2026 | 1,008.00 |
| Dec 31, 2025 | 203.00 |
| Sep 30, 2025 | -426.00 |
| Jun 30, 2025 | -702.00 |
| Mar 31, 2025 | -682.00 |
| Dec 31, 2024 | 990.00 |
| Sep 30, 2024 | 3,208.00 |
| Jun 30, 2024 | -1,614.00 |
| Mar 31, 2024 | 588.00 |
| Dec 31, 2023 | -482.00 |
| Sep 30, 2023 | -1,527.00 |
| Jun 30, 2023 | 682.00 |
| Mar 31, 2023 | 157.00 |
| Dec 31, 2022 | -980.00 |
| Sep 30, 2022 | -354.00 |
| Jun 30, 2022 | -884.00 |
| Mar 31, 2022 | -1,389.00 |
| Dec 31, 2021 | 1,871.00 |
| Sep 30, 2021 | 1,011.00 |